nomic evaluation of drug therapy. OBJECTIVES: This was to assess the cost effectiveness of some antimicrobial agents used in the treatment of sexually transmitted diseases (STD). These include doxycycline versus tetracycline for chlamydial infection, benzathine penicillin versus procaine penicillin for syphilis, and ceftriaxone versus spectinomycin for gonorrhoea. The choices were based on standard treatment guidelines and observed prescriptions. METHODS: Cost Effectiveness Analysis was used. The prescribed/dispensed prescriptions in STD clinic between 1997 and 1999 were reviewed retrospectively. Relevant information such as diagnosis, prescribed/ dispensed drugs, dosage, duration of therapy, laboratory results, physician's remarks among others were obtained from patient case-notes and dispensed prescriptions. In conjunction with these, time and motion studies and standard cost accounting technique were used. The cost per defined daily dose (DDD) and the cost of therapy for each agent were calculated. The cost components include overhead costs, and cost of drug/disposables acquisition. The literature was reviewed for positive and negative consequences of the considered therapeutic options. Improvements in signs and symptoms as well as eradication of the implicated organisms are the outcome measures. Decision table was used in the effectiveness rating. These were compared using chi square analysis. RESULTS: The results showed that doxycycline, benzathine penicillin and ceftriaxone were more effective than their respective counterparts in the treatment of stated infections. For example, doxycycline was N0.92 per unit effective while tetracycline was N1.82 per unit effective. Tetracycline is still widely used in the country. Alteration of some variables (cost and effectiveness rating) in favour of less cost effective option did not change the conclusion confirming that doxycycline is truly more cost effective. CONCLU-SION: It is concluded that tetracycline should no longer be used except when doxycycline is not available. This equally applies to benzathine penicillin and ceftriaxone compared to their counterparts. However patients peculiarities and contraindications need to be considered at all times. (2000) funded by the Agency for Healthcare Research and Quality. Hospitalizations due to cellulitis were identified using ICD-9 codes 681-682 as principal diagnoses. We assumed that 30-50% of cellulitis-related hospitalizations were caused by GAS. RESULTS: In 2000, there were approximately 110,000-183,000 hospitalizations due to GAS-associated cellulitis. Adults aged 18-64 years accounted for 56% of the hospitalizations, followed by the elderly (65 years and older, 36%) and children (<18 years, 8%). The most common comorbid conditions associated with cellulitis were hypertension (28%), diabetes mellitus (13%) and congestive heart failure (10%). The mean and median length of hospital stay for cellulitis were about five and four days, respectively. Total annual hospitalization charges for GAS-associated cellulitis were estimated at $1.2-2.0 billion in year 2002 US dollars. Average charge per hospital stay was about $10,500. CONCLUSIONS: GAS-associated cellulitis represents a significant economic burden in the US. Total annual hospitalization charges estimated for GAS-associated cellulitis are significantly higher than the recent estimate by the Institute of Medicine (Vaccines for the 21st Century, A Tool for Decisionmaking, 2000) for all GAS-associated hospitalizations (<$100 million). 
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HOSPITALIZATION EXPENDITURE OF STREPTOCOCCUS PYOGENES-ASSOCIATED CELLULITIS IN THE UNITED STATES
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THE COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) (PEGASYS) PLUS RIBAVIRIN (COPEGUS) VS. INTERFERON ALFA-2B PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C (CHC)
OBJECTIVES:
Peginterferon alfa-2a (40KD)/ribavirin (PEG) has been shown to produce a higher rate of sustained virological response (SVR) than non-pegylated combination therapy (non-PEG) in CHC, but the costeffectiveness of this improved efficacy has not been assessed. METHODS: We used a Markov model of disease progression in which the cohorts of hepatitis C virus (HCV) patients received PEG or non-PEG for either 48 or 24 weeks depending on genotype and liver histology and were followed for their expected lifetime. The reference patient was a 45-year-old male with CHC without cirrhosis. The SVRs to PEG and non-PEG were 46% and 36% for HCV genotype 1 and 76% and 61% for non-1, respectively. Quality of life and costs for each health state were based on literature and on Italian treatment patterns. Costs in 2002 Euros and benefits were discounted at 3%. RESULTS: In HCV genotype 1, PEG increases life expectancy (LY) by 0.78 years and qualityadjusted life expectancy (QALY) by 0.67 years compared to non-PEG. The incremental cost per QALY gained is 12,026 Euros. In HCV non-1 genotype patients, PEG increases LY by 1.17 and QALY by 1.01 years in com-parison to non-PEG. The incremental cost per QALY gained is €4289. The weighted average incremental cost-effectiveness ratio, using population-based HCV genotype distribution estimates, for all genotypes was €9473 per QALY. CONCLUSION: Peginterferon alfa-2a (40 KD)/ribavirin is a cost-effective therapy for treatment of naive adults with CHC compared with standard interferon alfa-2b/ribavirin, regardless of HCV genotype. 
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COST-EFFECTIVENESS ANALYSIS OF ANTI-VIRAL THERAPIES FOR CHRONIC HEPATITIS B IN TAIWAN
RESULTS:
For a 30-year-old chronic hepatitis B patient under base-case assumption, projected increase in life expectancy was 1.84 years, 2.01 years, and 3.9 years if s/he was treated with interferon, lamivudine for one year, and lamivudine for three years, respectively. ICERs (TWD/QALY) with 3% annual discount rate were 34,700 for interferon, 17,400 for 1 year of lamivudine, and 46,200 for 3 years of lamivudine. Monte Carlo simulation showed robust results with respect to a wide range of parameter assumptions and each of the three treatment regimens could result in costs-savings. In multi-way sensitivity analysis, the upper range of 95% of the ICERs (with 3% annual discount rate) were 204,100 for interferon, 127,800 for 1 year of lamivudine, and 197,900 for 3 years of lamivudine. CONCLUSIONS: Using lamivudine to treat of chronic hepatitis B among young adults in Taiwan would result in substantial gain in life expectancy.
